Given the lack of clarity on how G-CSF affects the risks of CRS, ICANS, cytopenias, and infections after CAR T, we retrospectively interrogated cohorts of patients treated with CAR T for lymphoma and multiple myeloma at our centers. This evidence concerns the gene CSF3 and plasma cell myeloma.